Ricevi le ultime notizie sulle azioni Intellia Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di NTLA

Ultime notizie per

INTELLIA THERAPEUTICS INC

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

News

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

ILMN

NTLA

OKLO

PATH

Scopri come queste strategie potrebbero influenzare il mercato e cosa riserva il futuro per questi investimenti.

Ecco in quali società sta investendo Cathie Wood tramite Ark

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

Earnings

Press Releases

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Health Care

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Legal

INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

General

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Ardelyx

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

Biohaven

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

89bio

GRAIL

Janux Therapeutics

MiMedx Group

MannKind

NuCana

Novavax

Precigen

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Stoke Therapeutics

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Chardan Capital

RBC Capital

Wells Fargo

HC Wainwright & Co.

Comments

Intellia Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO